Apimeds Pharmaceuticals US (APUS) Return on Capital Employed (2025)

Apimeds Pharmaceuticals US (APUS) reported Return on Capital Employed of 15.67% for Q4 2025, up 73.18% quarter-over-quarter from 58.44% in Q3 2025.

Apimeds Pharmaceuticals US (APUS) Return on Capital Employed (2025) Analysis & Trends

Apimeds Pharmaceuticals US has reported Return on Capital Employed for 1 years, with the latest figure at 15.67% in Q4 2025.

For the quarter ending Q4 2025, Return on Capital Employed changed N/A year-over-year to 15.67%; the trailing twelve-month figure through Dec 2025 stood at 15.67% (changed N/A YoY), and the FY2025 full-year result was 16.69%, down 17474.0% from the prior year.
Return on Capital Employed for Q4 2025 stood at 15.67%, up from 58.44% in the prior quarter.
The five-year high for Return on Capital Employed was 83.71% in Q1 2025, with the low at 78.44% in Q2 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	ROCE (Qtr)
1	Teva Pharmaceutical Industries	39.72 Bn	35.98 Bn	1.97 Bn	8.52%
2	Zoetis	34.61 Bn	32.67 Bn	1.62 Bn	27.58%
3	United Therapeutics	24.07 Bn	21.91 Bn	648.10 Mn	21.43%
4	Aurora Cannabis	16.98 Bn	16.91 Bn	33.43 Mn	-
5	Neurocrine Biosciences	16.64 Bn	15.32 Bn	800.70 Mn	20.04%
6	Elanco Animal Health	12.19 Bn	11.76 Bn	785.00 Mn	7.34%
7	Alkermes	7.37 Bn	6.86 Bn	-116.06 Mn	6.92%
8	Hims & Hers Health	6.62 Bn	5.87 Bn	396.79 Mn	-1.92%
9	Lantheus Holdings	6.47 Bn	5.97 Bn	230.92 Mn	14.85%
10	Apimeds Pharmaceuticals US	13.93 Mn	10.29 Mn	-	-15.67%

Download Data